TABLE 6.
Percent susceptible to imipenem-relebactam among Escherichia coli isolates susceptible or nonsusceptible to comparator agents
| Comparator agenta | I-R susceptible, proportion (%) |
P valueb | |
|---|---|---|---|
| If susceptible to comparator agent | If nonsusceptible to comparator agent | ||
| IPM | 90/90 (100) | 90/113 (80) | *** |
| MEM | 148/153 (97) | 32/50 (64) | *** |
| ETP | 5/7 (71) | 175/196 (89) | |
| GEN | 124/132 (94) | 56/71 (79) | ** |
| TZP | 55/56 (98) | 125/147 (85) | ** |
| AMK | 149/163 (91) | 31/40 (78) | * |
| LVX | 39/40 (98) | 141/163 (87) | * |
| TGC | 179/200 (90) | 1/3 (33) | * |
| CAZ | 17/19 (89) | 163/184 (89) | |
| CL | 178/201 (89) | 2/2 (100) | |
| MIN | 133/141 (94) | 47/62 (76) | *** |
a
AMK, amikacin; CAZ, ceftazidime; CL, colistin; ETP, ertapenem; GEN, gentamicin; IPM, imipenem; I-R, imipenem-relebactam; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; TGC, tigecycline; TZP, piperacillin-tazobactam.
b
P values as determined by chi-square test. *, P < 0.05; **, P < 0.01; ***, P ≤ 0.001.